Pub Date : 2025-02-01Epub Date: 2025-02-06DOI: 10.1097/PCC.0000000000003663
Matthew O Wiens, Enitan D Carrol, Mohammod Jobayer Chisti, Daniela Carla de Souza, Rakesh Lodha, Suchitra Ranjit, Niranjan Kissoon
{"title":"The 2024 Phoenix Sepsis Score Criteria: Part 4, What About Using World-Oriented Criteria?","authors":"Matthew O Wiens, Enitan D Carrol, Mohammod Jobayer Chisti, Daniela Carla de Souza, Rakesh Lodha, Suchitra Ranjit, Niranjan Kissoon","doi":"10.1097/PCC.0000000000003663","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003663","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e262-e265"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-02-06DOI: 10.1097/PCC.0000000000003665
Adrienne G Randolph, Mark W Hall, Niranjan Kissoon, Daniela Carla de Sousa, Mohammod Jobayer Chisti, Enitan D Carrol
{"title":"The 2024 Phoenix Sepsis Score Criteria: Part 5, What About \"Parsimony\" in the Criteria-Is Less Really More?","authors":"Adrienne G Randolph, Mark W Hall, Niranjan Kissoon, Daniela Carla de Sousa, Mohammod Jobayer Chisti, Enitan D Carrol","doi":"10.1097/PCC.0000000000003665","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003665","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e266-e271"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-02-06DOI: 10.1097/PCC.0000000000003683
Roelie M Wösten-van Asperen, Hannah M la Roi-Teeuw, Wim J E Tissing, Iolanda Jordan, Christian Dohna-Schwake, Gabriella Bottari, John Pappachan, Roman Crazzolara, Angela Amigoni, Agnieszka Mizia-Malarz, Andrea Moscatelli, María Sánchez-Martín, Jef Willems, Luregn J Schlapbach
Objectives: The Pediatric Sepsis Definition Task Force developed and validated a new organ dysfunction score, the Phoenix Sepsis Score (PSS), as a predictor of mortality in children with suspected or confirmed infection. The PSS showed improved performance compared with prior scores. However, the criteria were derived in a general pediatric population, in which only 10% had cancer. Given that pediatric cancer patients with sepsis have higher mortality compared with noncancer patients with sepsis, we aimed to assess the PSS in PICU patients with cancer and sepsis.
Design: Retrospective multicenter cohort study.
Setting: Twelve PICUs across Europe.
Patients: Each PICU identified patients 18 years young or younger, with underlying malignancy and suspected or proven sepsis, and admission between January 1, 2018, and January 1, 2020.
Interventions: None.
Measurements and main results: The PSS and three other scores, including Phoenix-8, Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score, and pediatric Sequential Organ Failure Assessment (pSOFA) score, were calculated for comparison. The primary outcome was 90-day all-cause mortality. We compared score performance using area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) analyses. Among 383 patients with proven or suspected sepsis, 90-day mortality was 19.3% (74/383). We failed to identify an association between a particular score and performance for 90-day mortality. The mean (95% CI) values for the AUROC of each score was: PSS 0.66 (0.59-0.72), Phoenix-8 0.65 (0.58-0.72), PELOD-2 0.64 (0.57-0.71), and pSOFA 0.67 (0.60-0.74) and for the AUPRC of each score: PSS 0.32 (0.23-0.42), Phoenix-8 0.32 (0.23-0.42), PELOD-2 0.32 (0.22-0.43), and pSOFA 0.36 (0.26-0.46). Similar results were obtained for PICU mortality or sepsis-related PICU mortality.
Conclusions: Contrary to the general PICU population, our retrospective test of the PSS in a PICU oncology dataset with suspected or proved sepsis from European PICUs, 2018-2020, failed to identify improved performance in association with mortality. This unique patient population deserves development of organ dysfunction scores that reflect organ dysfunction and mortality data specifically from these patients and will require prospective validation in future studies.
{"title":"The Phoenix Sepsis Score in Pediatric Oncology Patients With Sepsis at PICU Admission: Test of Performance in a European Multicenter Cohort, 2018-2020.","authors":"Roelie M Wösten-van Asperen, Hannah M la Roi-Teeuw, Wim J E Tissing, Iolanda Jordan, Christian Dohna-Schwake, Gabriella Bottari, John Pappachan, Roman Crazzolara, Angela Amigoni, Agnieszka Mizia-Malarz, Andrea Moscatelli, María Sánchez-Martín, Jef Willems, Luregn J Schlapbach","doi":"10.1097/PCC.0000000000003683","DOIUrl":"10.1097/PCC.0000000000003683","url":null,"abstract":"<p><strong>Objectives: </strong>The Pediatric Sepsis Definition Task Force developed and validated a new organ dysfunction score, the Phoenix Sepsis Score (PSS), as a predictor of mortality in children with suspected or confirmed infection. The PSS showed improved performance compared with prior scores. However, the criteria were derived in a general pediatric population, in which only 10% had cancer. Given that pediatric cancer patients with sepsis have higher mortality compared with noncancer patients with sepsis, we aimed to assess the PSS in PICU patients with cancer and sepsis.</p><p><strong>Design: </strong>Retrospective multicenter cohort study.</p><p><strong>Setting: </strong>Twelve PICUs across Europe.</p><p><strong>Patients: </strong>Each PICU identified patients 18 years young or younger, with underlying malignancy and suspected or proven sepsis, and admission between January 1, 2018, and January 1, 2020.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>The PSS and three other scores, including Phoenix-8, Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score, and pediatric Sequential Organ Failure Assessment (pSOFA) score, were calculated for comparison. The primary outcome was 90-day all-cause mortality. We compared score performance using area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) analyses. Among 383 patients with proven or suspected sepsis, 90-day mortality was 19.3% (74/383). We failed to identify an association between a particular score and performance for 90-day mortality. The mean (95% CI) values for the AUROC of each score was: PSS 0.66 (0.59-0.72), Phoenix-8 0.65 (0.58-0.72), PELOD-2 0.64 (0.57-0.71), and pSOFA 0.67 (0.60-0.74) and for the AUPRC of each score: PSS 0.32 (0.23-0.42), Phoenix-8 0.32 (0.23-0.42), PELOD-2 0.32 (0.22-0.43), and pSOFA 0.36 (0.26-0.46). Similar results were obtained for PICU mortality or sepsis-related PICU mortality.</p><p><strong>Conclusions: </strong>Contrary to the general PICU population, our retrospective test of the PSS in a PICU oncology dataset with suspected or proved sepsis from European PICUs, 2018-2020, failed to identify improved performance in association with mortality. This unique patient population deserves development of organ dysfunction scores that reflect organ dysfunction and mortality data specifically from these patients and will require prospective validation in future studies.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e177-e185"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-02-06DOI: 10.1097/PCC.0000000000003690
Robert C Tasker
{"title":"What Do We Know About Pediatric Sepsis Scoring Post-Phoenix?","authors":"Robert C Tasker","doi":"10.1097/PCC.0000000000003690","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003690","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e237-e240"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2024-12-19DOI: 10.1097/PCC.0000000000003661
Hasan S Kihtir, Muhterem Duyu, Mehmet E Mementoglu, Ilknur Tolunay, Tanil Kendirli, Faruk Ekinci, Edin Botan, Ebru A Ongun, Ayse Asik, Emrah Gun, Hacer Ucmak, Esra Sevketoglu, Dincer Yildizdas
Objectives: To examine citrate anticoagulation in continuous renal replacement therapy (CRRT) in the PICU.
Design: Post hoc analysis of a curated, multicenter dataset collected from January 1, 2022, to June 1, 2023.
Setting: Seven PICUs in Turkey.
Patients: PICU admissions in need of CRRT, 28 days to 18 years old.
Interventions: None.
Measurements and main results: In 128 filters used in 73 patients, the effective filter life (EFL) restricted to 72 hours was a median (interquartile range [IQR]) of 40.5 hours (IQR, 21-58 hr); total EFL was a median of 59 hours (IQR, 28-89 hr). Analysis of the receiver operating characteristic curve for initial citrate infusion dose (CID) and whether EFL reached 72 hours identified a cutoff level for initial CID of greater than 2.64 mmol citrate per liter of patient blood flow (mmol/L-bf). As expected, the two filter groups categorized by initial CID (≥ 2.7 vs. < 2.7 mmol/L-bf) showed filters in children receiving higher initial dosing had longer total EFL (72 hr [IQR, 48-104 hr] vs. 38.5 hr [IQR, 18-84 hr]; p = 0.03). We failed to identify an association between CRRT for over 24 or 48 hours and greater odds (odds ratio [OR], 95% CI) of citrate accumulation (OR, 2.23; 95% CI, 0.82-6.13; p = 0.118 or OR, 1.78; 95% CI, 0.84-3.8; p = 0.134, respectively). However, we cannot exclude up to 6.1- or 3.8-fold odds of citrate accumulation; of note, CRRT over 72 hours was associated with greater odds of citrate accumulation (OR, 2.17; 95% CI, 1.01-4.68; p = 0.04). Citrate lock syndrome occurred in eight of 128 (6.3%; 95% CI, 3-11.4%) filters, and resolved without termination of CRRT. On multivariable analysis, a higher patient initial lactate concentration was associated with an 18% (95% CI, 7-30%) greater hazard of developing citrate accumulation.
Conclusions: Citrate anticoagulation for CRRT is an option for children. Choosing an initial CID greater than or equal to 2.7 mmol/L-bf provides longer EFL but with the associated potential of citrate accumulation. Further studies are needed on initial CID and duration of EFL.
{"title":"Citrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes.","authors":"Hasan S Kihtir, Muhterem Duyu, Mehmet E Mementoglu, Ilknur Tolunay, Tanil Kendirli, Faruk Ekinci, Edin Botan, Ebru A Ongun, Ayse Asik, Emrah Gun, Hacer Ucmak, Esra Sevketoglu, Dincer Yildizdas","doi":"10.1097/PCC.0000000000003661","DOIUrl":"10.1097/PCC.0000000000003661","url":null,"abstract":"<p><strong>Objectives: </strong>To examine citrate anticoagulation in continuous renal replacement therapy (CRRT) in the PICU.</p><p><strong>Design: </strong>Post hoc analysis of a curated, multicenter dataset collected from January 1, 2022, to June 1, 2023.</p><p><strong>Setting: </strong>Seven PICUs in Turkey.</p><p><strong>Patients: </strong>PICU admissions in need of CRRT, 28 days to 18 years old.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>In 128 filters used in 73 patients, the effective filter life (EFL) restricted to 72 hours was a median (interquartile range [IQR]) of 40.5 hours (IQR, 21-58 hr); total EFL was a median of 59 hours (IQR, 28-89 hr). Analysis of the receiver operating characteristic curve for initial citrate infusion dose (CID) and whether EFL reached 72 hours identified a cutoff level for initial CID of greater than 2.64 mmol citrate per liter of patient blood flow (mmol/L-bf). As expected, the two filter groups categorized by initial CID (≥ 2.7 vs. < 2.7 mmol/L-bf) showed filters in children receiving higher initial dosing had longer total EFL (72 hr [IQR, 48-104 hr] vs. 38.5 hr [IQR, 18-84 hr]; p = 0.03). We failed to identify an association between CRRT for over 24 or 48 hours and greater odds (odds ratio [OR], 95% CI) of citrate accumulation (OR, 2.23; 95% CI, 0.82-6.13; p = 0.118 or OR, 1.78; 95% CI, 0.84-3.8; p = 0.134, respectively). However, we cannot exclude up to 6.1- or 3.8-fold odds of citrate accumulation; of note, CRRT over 72 hours was associated with greater odds of citrate accumulation (OR, 2.17; 95% CI, 1.01-4.68; p = 0.04). Citrate lock syndrome occurred in eight of 128 (6.3%; 95% CI, 3-11.4%) filters, and resolved without termination of CRRT. On multivariable analysis, a higher patient initial lactate concentration was associated with an 18% (95% CI, 7-30%) greater hazard of developing citrate accumulation.</p><p><strong>Conclusions: </strong>Citrate anticoagulation for CRRT is an option for children. Choosing an initial CID greater than or equal to 2.7 mmol/L-bf provides longer EFL but with the associated potential of citrate accumulation. Further studies are needed on initial CID and duration of EFL.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e216-e226"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2024-12-24DOI: 10.1097/PCC.0000000000003677
Tran Dang Xoay, Ta Anh Tuan, Nguyen Thi Ha, Thieu Quang Quan, Nguyen Thi Duyen, Tran Thi Kieu My
Objectives: To assess antithrombin and activated protein C (aPC) levels in relation to disseminated intravascular coagulation (DIC) and severe outcomes in pediatric sepsis.
Design: Prospective, observational study conducted between April 2023 and October 2024. Coagulation profiles including conventional coagulation, antithrombin activity, and aPC were obtained at PICU admission.
Setting: PICU in the Vietnam National Children's Hospital, Hanoi, Vietnam.
Subjects: PICU admissions, 1 month to 18 years old, with sepsis.
Interventions: None.
Measurements and main results: One hundred thirty children (78 males; median age 7.5 mo) with mortality 23/130 (17.7%). The prevalence of overt DIC was 37 of 130 (28.5%). Nonsurvival at 28 days, compared with survival, was associated with hemorrhage and/or thrombosis at presentation, and higher number of dysfunctional organs, and overt DIC. Those with overt DIC, compared with not, had longer activated partial thromboplastin time, higher international normalized ratio and d -dimer, and lower antithrombin, and aPC. Activity of antithrombin and aPC correlated inversely with the Vasoactive-Inotropic Score in survivors ( p = 0.002 and 0.009, respectively). Patients with a cutoff value for antithrombin less than 63.5% had a mortality risk with area under the receiver operating characteristic (AUROC) curve 0.64, with sensitivity 0.51 and specificity 0.74, and positive predictive value 0.30. Regarding overt DIC, a cutoff value for antithrombin less than 55.5% had an AUROC 0.78, sensitivity 0.72 and specificity of 0.73, and positive predictive value 0.52.
Conclusions: In this observational study of pediatric sepsis patients, first 24-hour coagulation data in those who did not-survive to 28 days, vs. survivors showed an associated prior lower level of antithrombin in nonsurvivors. Furthermore, using the outcome of overt DIC and nonovert DIC in the first 72 hours, we found that lower levels of antithrombin or aPC are each associated with overt DIC and nonovert DIC in pediatric sepsis. Further validation work is needed in larger case series of pediatric sepsis.
{"title":"Antithrombin and Activated Protein C in Pediatric Sepsis: Prospective Observational Study of Outcome.","authors":"Tran Dang Xoay, Ta Anh Tuan, Nguyen Thi Ha, Thieu Quang Quan, Nguyen Thi Duyen, Tran Thi Kieu My","doi":"10.1097/PCC.0000000000003677","DOIUrl":"10.1097/PCC.0000000000003677","url":null,"abstract":"<p><strong>Objectives: </strong>To assess antithrombin and activated protein C (aPC) levels in relation to disseminated intravascular coagulation (DIC) and severe outcomes in pediatric sepsis.</p><p><strong>Design: </strong>Prospective, observational study conducted between April 2023 and October 2024. Coagulation profiles including conventional coagulation, antithrombin activity, and aPC were obtained at PICU admission.</p><p><strong>Setting: </strong>PICU in the Vietnam National Children's Hospital, Hanoi, Vietnam.</p><p><strong>Subjects: </strong>PICU admissions, 1 month to 18 years old, with sepsis.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>One hundred thirty children (78 males; median age 7.5 mo) with mortality 23/130 (17.7%). The prevalence of overt DIC was 37 of 130 (28.5%). Nonsurvival at 28 days, compared with survival, was associated with hemorrhage and/or thrombosis at presentation, and higher number of dysfunctional organs, and overt DIC. Those with overt DIC, compared with not, had longer activated partial thromboplastin time, higher international normalized ratio and d -dimer, and lower antithrombin, and aPC. Activity of antithrombin and aPC correlated inversely with the Vasoactive-Inotropic Score in survivors ( p = 0.002 and 0.009, respectively). Patients with a cutoff value for antithrombin less than 63.5% had a mortality risk with area under the receiver operating characteristic (AUROC) curve 0.64, with sensitivity 0.51 and specificity 0.74, and positive predictive value 0.30. Regarding overt DIC, a cutoff value for antithrombin less than 55.5% had an AUROC 0.78, sensitivity 0.72 and specificity of 0.73, and positive predictive value 0.52.</p><p><strong>Conclusions: </strong>In this observational study of pediatric sepsis patients, first 24-hour coagulation data in those who did not-survive to 28 days, vs. survivors showed an associated prior lower level of antithrombin in nonsurvivors. Furthermore, using the outcome of overt DIC and nonovert DIC in the first 72 hours, we found that lower levels of antithrombin or aPC are each associated with overt DIC and nonovert DIC in pediatric sepsis. Further validation work is needed in larger case series of pediatric sepsis.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e197-e205"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-01-02DOI: 10.1097/PCC.0000000000003688
Lee A Polikoff
{"title":"Phoenix Rising: External Validation of the Phoenix Sepsis Criteria.","authors":"Lee A Polikoff","doi":"10.1097/PCC.0000000000003688","DOIUrl":"10.1097/PCC.0000000000003688","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e241-e243"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-02-06DOI: 10.1097/PCC.0000000000003655
Eran Shostak, Ovadia Dagan, Yelena Tzeitlin, Ori Goldberg, Gal Raz, Gabriel Amir, Yael Feinstein, Ofer Schiller
Objectives: There are several options for durable venous access for pediatric cardiac patients and the insertion techniques, locations, and complications potentially differ. The study aimed to evaluate our experience of upper extremity peripherally inserted central catheters (PICCs) and durable tunneled femoral central venous catheters (TF-CVCs) in young pediatric cardiac ICU (PCICU) patients.
Design: Retrospective cohort study, 2015-2021.
Setting: PCICU in a tertiary medical care center.
Patients: All patients younger than 1.5 years old who underwent bedside insertion of TF-CVC or upper extremity PICC between December 2015 and December 2021.
Interventions: None.
Measurements and main results: The cohort included 226 durable lines, inserted in patients 2-550 days old, with 111 upper extremity PICCs and 115 TF-CVCs. In the two groups, receipt of PICC vs. TF-CVC placement was associated with older age (125.6 vs. 53.4 d; p = 0.005), and shorter duration of mechanical ventilation (9.0 vs. 25.5 d; p < 0.001). PICC vs. TF-CVC use was associated with a higher rate of central line-associated bloodstream infection (CLABSI) (7.14 vs. 2.38/1000 line days; p = 0.004) and more thrombosis events (5 vs. 0; p = 0.008). When adjusted for CLABSI-free line days, TF-CVCs (relative to upper limb PICCs) was associated with close to one-third of the odds of CLABSI (odds ratio [OR], 0.31 [95% CI, 0.13-0.78]); similarly, when adjusted for line days close to one-third of the odds of any complication, that is, CLABSI, dislodgment, occlusion, or thrombosis (OR, 0.31 [95% CI, 0.14-0.65]).
Conclusions: In our 2015-2021 PCICU experience of using durable TF-CVC inserted at the bedside, vs. upper extremity PICCs, in neonates and infants, we found an associated one-third the odds of CLABSI and overall complications. A prospective study of subcutaneous tunneling in various locations of catheters on CLABSI and overall complication rates is needed.
{"title":"Durable Central Venous Access for Pediatric Cardiac Patients: Secondary Analysis of a Single-Center, Retrospective Cohort Study, 2015-2021.","authors":"Eran Shostak, Ovadia Dagan, Yelena Tzeitlin, Ori Goldberg, Gal Raz, Gabriel Amir, Yael Feinstein, Ofer Schiller","doi":"10.1097/PCC.0000000000003655","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003655","url":null,"abstract":"<p><strong>Objectives: </strong>There are several options for durable venous access for pediatric cardiac patients and the insertion techniques, locations, and complications potentially differ. The study aimed to evaluate our experience of upper extremity peripherally inserted central catheters (PICCs) and durable tunneled femoral central venous catheters (TF-CVCs) in young pediatric cardiac ICU (PCICU) patients.</p><p><strong>Design: </strong>Retrospective cohort study, 2015-2021.</p><p><strong>Setting: </strong>PCICU in a tertiary medical care center.</p><p><strong>Patients: </strong>All patients younger than 1.5 years old who underwent bedside insertion of TF-CVC or upper extremity PICC between December 2015 and December 2021.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>The cohort included 226 durable lines, inserted in patients 2-550 days old, with 111 upper extremity PICCs and 115 TF-CVCs. In the two groups, receipt of PICC vs. TF-CVC placement was associated with older age (125.6 vs. 53.4 d; p = 0.005), and shorter duration of mechanical ventilation (9.0 vs. 25.5 d; p < 0.001). PICC vs. TF-CVC use was associated with a higher rate of central line-associated bloodstream infection (CLABSI) (7.14 vs. 2.38/1000 line days; p = 0.004) and more thrombosis events (5 vs. 0; p = 0.008). When adjusted for CLABSI-free line days, TF-CVCs (relative to upper limb PICCs) was associated with close to one-third of the odds of CLABSI (odds ratio [OR], 0.31 [95% CI, 0.13-0.78]); similarly, when adjusted for line days close to one-third of the odds of any complication, that is, CLABSI, dislodgment, occlusion, or thrombosis (OR, 0.31 [95% CI, 0.14-0.65]).</p><p><strong>Conclusions: </strong>In our 2015-2021 PCICU experience of using durable TF-CVC inserted at the bedside, vs. upper extremity PICCs, in neonates and infants, we found an associated one-third the odds of CLABSI and overall complications. A prospective study of subcutaneous tunneling in various locations of catheters on CLABSI and overall complication rates is needed.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e137-e145"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-01-02DOI: 10.1097/PCC.0000000000003682
Michael J Carter, Joshua Hageman, Yael Feinstein, Jethro Herberg, Myrsini Kaforou, Mark J Peters, Simon Nadel, Naomi Edmonds, Nazima Pathan, Michael Levin, Padmanabhan Ramnarayan
Objectives: To assess characteristics and outcomes of children with suspected or confirmed infection requiring emergency transport and PICU admission and to explore the association between the 2024 Phoenix Sepsis Score (PSS) criteria and mortality.
Design: Retrospective analysis of curated data from a 2014-2016 multicenter cohort study.
Setting: PICU admission following emergency transport in South East England, United Kingdom, from April 2014 to December 2016.
Patients: Children 0-16 years old ( n = 663) of whom 444 (67%) had suspected or confirmed infection.
Interventions: None.
Measurements and main results: The PSS was calculated as a sum of four individual organ subscores (respiratory, cardiovascular, neurological, and coagulation) using the worst values during transport (i.e., from referral until the time of PICU admission). A score cutoff of greater than or equal to 2 points was used to define sepsis; and septic shock was defined as sepsis plus 1 or more cardiovascular subscore points. Sepsis occurred in 260 of 444 children (58.6%) with suspected or confirmed infection, with septic shock occurring in 177 of 260 (68.1%) of those with sepsis. A PSS score greater than or equal to 2 points occurred in 37 of 67 bronchiolitis cases, 19 of 35 meningoencephalitis cases, 30 of 47 pneumonia/empyema cases, 38 of 46 septic/toxic shock cases, nine of 15 severe sepsis cases, and 58 of 118 definite viral infections. Overall, 14 of 444 children died (3.2%). There were 12 deaths in the 260 children with PSS greater than or equal to 2, and two deaths in the 184 children with PSS less than 2 (4.6% vs. 1.1%; absolute difference, 3.5%; 95% CI, 0.1-6.9%; p = 0.04).
Conclusions: In 2014-2016, over half of the critically ill children undergoing emergency transport to PICU with presumed or confirmed infection, and meeting retrospectively applied PSS criteria for sepsis, had a range of clinical diagnoses including bronchiolitis, meningoencephalitis, and pneumonia/empyema. Furthermore, the PSS criteria for categorization of sepsis and septic shock were associated with outcome and may be of value in future risk-stratification in clinical trials.
目的:评估疑似或确诊感染需要紧急转运和PICU入院的儿童的特征和结局,并探讨2024 Phoenix脓毒症评分(PSS)标准与死亡率之间的关系。设计:回顾性分析2014-2016年多中心队列研究的整理数据。背景:2014年4月至2016年12月,英国英格兰东南部紧急转运后入院PICU。患者:0-16岁儿童(n = 663),其中444例(67%)疑似或确诊感染。干预措施:没有。测量和主要结果:PSS计算为四个单独器官评分(呼吸、心血管、神经和凝血)的总和,使用运输期间(即从转诊到PICU入院)的最差值。脓毒症采用大于或等于2分的评分截止;脓毒性休克定义为脓毒症加上1个或更多的心血管亚评分。444例疑似或确诊感染患儿中有260例(58.6%)发生脓毒症,260例脓毒症患儿中有177例(68.1%)发生脓毒症休克。67例细支气管炎患者中有37例PSS评分大于等于2分,35例脑膜脑炎患者中有19例,47例肺炎/脓肿患者中有30例,46例脓毒症/中毒性休克患者中有38例,15例严重脓毒症患者中有9例,118例明确病毒感染患者中有58例。总体而言,444名儿童中有14人死亡(3.2%)。260例大于或等于2的PSS患儿中有12例死亡,184例小于2的PSS患儿中有2例死亡(4.6% vs. 1.1%;绝对差,3.5%;95% ci, 0.1-6.9%;P = 0.04)。结论:2014-2016年,超过半数推定或确诊感染并符合回顾性应用PSS脓毒症标准的危重患儿被紧急送往PICU,其临床诊断包括细支气管炎、脑膜脑炎和肺炎/脓胸。此外,PSS对脓毒症和脓毒性休克的分类标准与结果相关,可能对未来临床试验中的风险分层有价值。
{"title":"Evaluation of Phoenix Sepsis Score Criteria: Exploratory Analysis of Characteristics and Outcomes in an Emergency Transport PICU Cohort From the United Kingdom, 2014-2016.","authors":"Michael J Carter, Joshua Hageman, Yael Feinstein, Jethro Herberg, Myrsini Kaforou, Mark J Peters, Simon Nadel, Naomi Edmonds, Nazima Pathan, Michael Levin, Padmanabhan Ramnarayan","doi":"10.1097/PCC.0000000000003682","DOIUrl":"10.1097/PCC.0000000000003682","url":null,"abstract":"<p><strong>Objectives: </strong>To assess characteristics and outcomes of children with suspected or confirmed infection requiring emergency transport and PICU admission and to explore the association between the 2024 Phoenix Sepsis Score (PSS) criteria and mortality.</p><p><strong>Design: </strong>Retrospective analysis of curated data from a 2014-2016 multicenter cohort study.</p><p><strong>Setting: </strong>PICU admission following emergency transport in South East England, United Kingdom, from April 2014 to December 2016.</p><p><strong>Patients: </strong>Children 0-16 years old ( n = 663) of whom 444 (67%) had suspected or confirmed infection.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>The PSS was calculated as a sum of four individual organ subscores (respiratory, cardiovascular, neurological, and coagulation) using the worst values during transport (i.e., from referral until the time of PICU admission). A score cutoff of greater than or equal to 2 points was used to define sepsis; and septic shock was defined as sepsis plus 1 or more cardiovascular subscore points. Sepsis occurred in 260 of 444 children (58.6%) with suspected or confirmed infection, with septic shock occurring in 177 of 260 (68.1%) of those with sepsis. A PSS score greater than or equal to 2 points occurred in 37 of 67 bronchiolitis cases, 19 of 35 meningoencephalitis cases, 30 of 47 pneumonia/empyema cases, 38 of 46 septic/toxic shock cases, nine of 15 severe sepsis cases, and 58 of 118 definite viral infections. Overall, 14 of 444 children died (3.2%). There were 12 deaths in the 260 children with PSS greater than or equal to 2, and two deaths in the 184 children with PSS less than 2 (4.6% vs. 1.1%; absolute difference, 3.5%; 95% CI, 0.1-6.9%; p = 0.04).</p><p><strong>Conclusions: </strong>In 2014-2016, over half of the critically ill children undergoing emergency transport to PICU with presumed or confirmed infection, and meeting retrospectively applied PSS criteria for sepsis, had a range of clinical diagnoses including bronchiolitis, meningoencephalitis, and pneumonia/empyema. Furthermore, the PSS criteria for categorization of sepsis and septic shock were associated with outcome and may be of value in future risk-stratification in clinical trials.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e186-e196"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2025-02-06DOI: 10.1097/PCC.0000000000003662
Mark W Hall, Rakesh Lodha, Niranjan Kissoon, Adrienne G Randolph
{"title":"The 2024 Phoenix Sepsis Score Criteria: Part 3, What About Using Stages of Sepsis in the Criteria?","authors":"Mark W Hall, Rakesh Lodha, Niranjan Kissoon, Adrienne G Randolph","doi":"10.1097/PCC.0000000000003662","DOIUrl":"https://doi.org/10.1097/PCC.0000000000003662","url":null,"abstract":"","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":"26 2","pages":"e256-e261"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}